Health Care Sector Rating: Neutral
Following the worst of the COVID-19 crisis, elective care has resumed, high expenses related to COVID-19 patient care have subsided, and medical equipment and pharmaceutical stocks have followed the market higher. Meanwhile, the sector has many favorable long-term attributes, such as new cost-saving and care-improving advances in medical technologies, an aging global population, and a growing middle class in emerging-market economies—all of whom will demand more extensive drug treatments and medical care over time. Valuations are relatively attractive, and balance sheets in the sector are generally in good shape, increasing the possibility of higher dividend payments, share-enhancing stock buybacks, and mergers-and-acquisition (M&A) activity.
There are signs of peaking in the rate of economic growth. This has historically been a tailwind for the Health Care sector.
There are still risks, however. Any legislation to control drug prices or raise corporate taxes could weigh on pharmaceutical companies' profits—although promising pipeline drugs can mitigate these risks.
The Russian invasion of Ukraine in late February, and the ongoing political response, has clouded our outlook on equity sectors. Due to the unprecedented and volatile series of events, the economic and market landscape has become highly uncertain.
Until there is more clarity on how the sharp rise in commodity prices, tightening of financial conditions, and likely Federal Reserve interest rate hikes might impact the economy and underlying fundamentals that drive relative sector performance, we think it’s prudent to maintain sector allocations that are in line with the overall market.
Positives for the sector:
- Peaking economic growth has historically been relatively favorable for this defensive sector—though sector rotation is likely going to be choppy
- Strong balance sheets, with ample cash for dividends and M&A
- Positive long-term demographics trends, including an aging global population and a growing middle class in emerging markets
- Return in demand for elective procedures, drug sales, medical equipment and diagnostics
- Valuations are attractive relative to the sector's historical average
- Biotech and pharmaceuticals have strong drug development pipeline
- Supreme Court rejected latest challenge to ACA
Negatives for the sector:
- Extended-care facilities have seen a decline in enrollments and are likely to see higher costs related to virus mitigation requirements
Risks for the sector:
- Prescription drug price controls and other regulations
- Target of anti-competitive regulation
- Surge in COVID-19 variants could reduce demand for elective medical care
- New competition from Amazon Care, a hybrid telehealth/in-person health care offering
What do the ratings mean?
The sectors we analyze are from the widely recognized Global Industry Classification Standard (GICS®) groupings. After a review of risks and opportunities, we give each stock sector one of the following ratings:
- Outperform: likely to perform better than the broader stock market*
- Underperform: likely to perform worse than the broader stock market*
- Neutral: no current view on likely relative performance
* As represented by the S&P 500 index
Want to learn more about a specific sector? Click on a link below for more information or visit Schwab Sector Views to see how they compare. Clients can log in to see our top-rated stocks in the Health Care sector.
- Review your sector allocation. If you aren’t sure how to analyze your sector weightings, a Schwab Financial Consultant can help.
- Talk to us about the services that are right for you. Call us at , , or .
Schwab Sector Views do not represent a personalized recommendation of a particular investment strategy to you. You should not buy or sell an investment without first considering whether it is appropriate for you and your portfolio. Additionally, you should review and consider any recent market news.
All expressions of opinion are subject to change without notice in reaction to shifting market conditions. Data contained herein from third-party providers is obtained from what are considered reliable sources. However, its accuracy, completeness or reliability cannot be guaranteed. Supporting documentation for any claims or statistical information is available upon request.
Forecasts contained herein are for illustrative purposes only, may be based upon proprietary research and are developed through analysis of historical public data.
Past performance is no guarantee of future results and the opinions presented cannot be viewed as an indicator of future performance.
Investing involves risk including loss of principal.
Indexes are unmanaged, do not incur management fees, costs and expenses and cannot be invested in directly. For more information on indexes please see www.schwab.com/indexdefinitions.
The policy analysis provided by the Charles Schwab and Co., Inc., does not constitute and should not be interpreted as an endorsement of any political party.
All corporate names are for illustrative purposes only and are not a recommendation, offer to sell, or a solicitation of an offer to buy any security.
Commodity-related products, including futures, carry a high level of risk and are not suitable for all investors. Commodity‐related products may be extremely volatile, illiquid and can be significantly affected by underlying commodity prices, world events, import controls, worldwide competition, government regulations, and economic conditions, regardless of the length of time shares are held.
The Schwab Center for Financial Research (SCFR) is a division of Charles Schwab & Co., Inc.